Docetaxel-oxaliplatin-capecitabine/5-fluorouracil (DOX/F) followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil (CAPOX/FOLFOX) in HER2-negative advanced gastric cancers
JNCI Cancer Spectrum · 01.07.2024 · 8 (4)
DOI: 10.1093/jncics/pkae054 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JNCI Cancer Spectrum, online erschienen am 27.07.2024. Verfasst von Anant Ramaswamy und 41 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India. Hauptthemen laut MEDLINE: Adenocarcinoma, Antineoplastic Combined Chemotherapy Protocols, Capecitabine, Docetaxel. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: TMC Research Administrative Council (TRAC) Tata Memorial Centre, Nag Foundation Grant to the institute.
Abstract (Originalsprache)
Background
We evaluated whether the addition of docetaxel (D) to a combination comprising 5-fluorouracil/leucovorin (5-FU/LV) or capecitabine (C) plus oxaliplatin (O) (DOF/DOX) improved overall survival (OS) compared with 6 months of 5-fluorouracil (5-FU) or capecitabine in combination with oxaliplatin (FOLFOX/CAPOX) alone in advanced HER2-negative gastroesophageal junction and gastric adenocarcinomas (G/GEJ).
Methods
This study was an investigator-initiated, open-label, multi-institutional, randomized phase III trial in adult patients with HER2-negative advanced G/GEJs. The primary endpoint of the study was a comparison of median OS by Kaplan-Meier method. Next-generation sequencing was performed on tissue.
Results
Of the 324 patients randomly assigned between July 2020 and November 2022, 305 patients were evaluable for analysis (FOLFOX/CAPOX: 156; DOF/DOX: 149). With a median follow-up time of 19.2 months (95% Confidence Interval [CI] = 16.5 months to 21.9 months) for the entire cohort, the median OS was 10.1 months (95% CI = 9.2 to 10.9) for FOLFOX/CAPOX and 8.9 months (95% CI = 7.3 to 10.5) for DOF/DOX, and this difference was not statistically significant (P = .70). An increased proportion of grade 3 or grade 4 neutropenia (21% vs 3%; P < .001) and grade 2/3 neuropathy (17% vs 7%; P = .005) was seen in patients receiving DOF/DOX. Genomic profiling revealed a low incidence of microsatellite instability (1%) and a high incidence of BRCA1 (8.4%) and BRCA2 (7.5%) somatic alterations.
Conclusion
FOLFOX or CAPOX chemotherapy for 6 months remains one of the standards of care in advanced HER2-negative gastroesophageal junction and gastric adenocarcinomas, with no additional survival benefit seen with the addition of docetaxel. Genomic profiling of patients revealed a higher than previously known incidence of somatic BRCA alterations, which requires further evaluation. CTRI (Clinical Trial Registry of India: CTRI/2020/03/023944).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India.
- Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.
- Department of Medical Oncology, Homi Bhabha Cancer Hospital, Varanasi, India.
- Department of Molecular Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India.
- Consultant Medical Oncologist, P.D. Hinduja Hospital & Medical Research Centre, Mumbai, India.
- Department of Surgical Oncology, Homi Bhabha Cancer Hospital, Varanasi, India.
ORCID-Profile: Anant Ramaswamy, Vanita Noronha, Vikas Ostwal
Förderung
- TMC Research Administrative Council (TRAC) Tata Memorial Centre
- Nag Foundation Grant to the institute
Zitieren
APA
Ramaswamy, A., Bhargava, P., Dubashi, B., Gupta, A., Kapoor, A., Srinivas, S., Shetty, O., Jadhav, P., Desai, V., Noronha, V., Joshi, A., Menon, N., Patil, V. M., Mishra, B. K., Sansar, B., Singh, A., Patel, S., Singh, S. N., Dhal, I., …, & Ostwal, V. (2024). Docetaxel-oxaliplatin-capecitabine/5-fluorouracil (DOX/F) followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil (CAPOX/FOLFOX) in HER2-negative advanced gastric cancers. JNCI Cancer Spectrum, 8(4). https://doi.org/10.1093/jncics/pkae054
Vancouver
Ramaswamy A, Bhargava P, Dubashi B, Gupta A, Kapoor A, Srinivas S, et al. Docetaxel-oxaliplatin-capecitabine/5-fluorouracil (DOX/F) followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil (CAPOX/FOLFOX) in HER2-negative advanced gastric cancers. JNCI Cancer Spectrum. 2024;8(4). doi:10.1093/jncics/pkae054
BibTeX
@article{Ramaswamy2024,
author = {Ramaswamy, Anant and Bhargava, Prabhat and Dubashi, Biswajit and Gupta, Anuj and Kapoor, Akhil and Srinivas, Sujay and Shetty, Omshree and Jadhav, Poonam and Desai, Veena and Noronha, Vanita and Joshi, Amit and Menon, Nandini and Patil, Vijay M and Mishra, Bal Krishna and Sansar, Bipinesh and Singh, Arpita and Patel, Swapnil and Singh, Satyendra Narayan and Dhal, Ipsita and Vinayak, Kunal Ranjan and Pal, Vikash and Mandavkar, Sarika and Kannan, Sadhana and Chaugule, Deepali and Patil, Rajshree and Parulekar, Manali and Nashikkar, Chaitali and Ankathi, Suman Kumar and Kaushal, Rajiv Kumar and Shah, Aekta and Ganesan, Prasanth and Kayal, Smita and Ananthakrishnan, Ramesh and Syed, Noorzia and Samaddar, Debdeep and Kapu, Venkatesh and Shah, Anokhi and Kaaviya, D and Suganiya, R and Srinivasan, Nirmala Devi and Prabhash, Kumar and Ostwal, Vikas},
title = {Docetaxel-oxaliplatin-capecitabine/5-fluorouracil (DOX/F) followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil (CAPOX/FOLFOX) in HER2-negative advanced gastric cancers},
journal = {JNCI Cancer Spectrum},
year = {2024},
volume = {8},
number = {4},
doi = {10.1093/jncics/pkae054}
}
EUVIMED